A pilot survey of legacy and current commercial fluorinated chemicals in human sera from United States donors in 2009.

Human biomonitoring has traditionally focused on analyzing the perfluorocarboxylates (PFCAs) and perfluorosulfonates (PFSAs), although the presence of other unidentified fluorinated chemicals has been demonstrated through total organofluorine analysis. Exposure to legacy and current commercial fluorinated chemicals was investigated by analyzing fifty human sera samples collected in 2009 from the United States for forty fluorinated analytes that included the polyfluoroalkyl phosphate diesters (diPAPs), N-ethyl perfluorooctanesulfonamidoethanol-based polyfluoroalkyl phosphate diester (SAmPAP), one fluorotelomer mercaptoalkyl phosphate diester congener (FTMAP), fluorotelomer sulfonates (FTSs), perfluorophosphonates (PFPAs), and perfluorophosphinates (PFPiAs). DiPAP concentrations (0.035-0.136 μg/L) for the more dominant congeners (6:2, 6:2/8:2, 8:2) were lower than those reported in human sera samples collected in 2004, 2005, and 2008. The SAmPAP and 6:2 FTMAP were not detected, but exposure to SAmPAP was suggested based on the detection of one of its potential degradation intermediates, N-ethyl perfluorooctanesulfonamidoacetate (N-EtFOSAA). PFPiAs were detected for the first time in human sera, with C6/C6 and C6/C8 PFPiAs as the dominant congeners, observed in >50% of the samples.